The bone mineral densities of the lumbar spine and femoral neck were determined by dual energy x ray absorptiometry in 110 women aged 40-82 years (average 65 years) with spinal osteoporosis who had had at least one atraumatic vertebral compression fracture and in 1026 normal women aged 40-79 years (average 52 years). The women with osteoporosis showed a significant decrease in bone mineral density (BMD) at the lumbar spine and femoral neck compared with age matched normal women (sixth decade of life -26% spine, -23% femoral neck; seventh decade -26% spine, -16% femoral neck).
Bone mass cannot be substantially increased once osteoporotic fractures have occurred and at present the only viable approach to halting the growing epidemic of osteoporosis appears to be the prevention of bone loss. Consequently the measurement of bone mineral density (BMD) is being increasingly requested by doctors to assess a woman's risk of osteoporotic fracture. This part played by bone densitometry is supported by the recognition that bone mass is the most important determinant of bone strength with a relative risk offracture increasing about twofold for every one Measurements of BMD were made at the lumbar spine and neck of femur. The spinal value was calculated as an average of the BMD from L1 to L4 and the femoral neck value was derived from a region of interest identified by the QDR-1000 software as a 15 cm band adjacent to the greater trochanter. Long term precision errors, estimated with daily BMD measurements using an anthropomorphic spine phantom, were 0-38% and the in vivo precision by four repeated measurements on three normal subjects over two weeks gave a coefficient of variation of 1-1% for the lumbar spine and 1 2% for the neck of femur. Two repeated measurements on the same day on 49 subjects with osteoporotic vertebral collapse gave a coefficient of variation of 1 6% for the lumbar spine and 1-2% for the femoral neck. Statistical analysis was performed using the paired t test. 3 and 4) show that the mean BMD will reach the fracture threshold about 18 years after menopause at the lumbar spine and after 15 years at the femoral neck. This also implies that to keep their BMD above the fracture threshold by the age of 70 years, at least 50% of postmenopausal women will have to be treated.
For women aged 70-90 years further bone loss will have occurred. Estimates for normal rates of bone loss in the elderly have varied between 0-2 and 1%,7 16 but any further bone loss will mean that most women will eventually have a BMD below the fracture threshold. Therefore if the aim of treatment is to maintain women above the fracture threshold for life, then most will need hormone replacement therapy. This implies that for most women BMD measurements should be performed to assess the duration of hormone replacement therapy. For assessment of the risk of osteoporosis and which subjects require hormone replacement therapy, however, BMD measurements, though remaining useful, will have a decreased part to play. On the basis of data expressed in this paper it should be possible to generate tables showing the necessary duration of hormone replacement therapy based on age at menopause or, if unknown, the chronological age, BMD and life expectancy. Serial measurements of BMD would allow refinements to be made to these recommendations.
